Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics

Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by TD Cowen analyst, Tyler Van Buren.

Tyler Van Buren has given his Buy rating due to a combination of factors that highlight the promising potential of Maze Therapeutics, Inc.’s drug candidates. The company’s oral APOL1 inhibitor, MZE829, is positioned to address a significant portion of the over 1 million patients with APOL1-mediated kidney disease (AKD). With a potency approximately 100 times greater than Vertex’s inaxaplin, MZE829 has the potential to become a leading treatment in this space, with expected sales reaching around $2 billion by 2035 if it achieves the desired outcomes in its Phase II HORIZON trial.
Additionally, Maze Therapeutics’ MZE782, an oral SLC6A19 inhibitor, is a pioneering treatment targeting chronic kidney disease (CKD) and phenylketonuria (PKU). By mimicking the protective effects of a specific genetic variant, MZE782 offers a novel approach with a de-risked development path, bolstered by its superior potency compared to existing treatments. The potential market impact of MZE782 is substantial, with projected sales of $2.6 billion by 2035. These factors collectively underpin Van Buren’s optimistic outlook and Buy rating for Maze Therapeutics’ stock.

In another report released today, Guggenheim also initiated coverage with a Buy rating on the stock with a $19.00 price target.